Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of Hydronidone in Hepatic Impairment
NCT07394309Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of hydronidone in Liver Fibrosis (LF) (3 arms), sponsored by Gyre Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of Hydronidone at 48 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration of Hydronidone at 48 hours and 8 more. Started Mar 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07394309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394309.